Pharmaids Pharmaceuticals' Q1 FY 2026-27 Quarterly Results

Result Summary

• Pharmaids Pharmaceuticals Ltd reported a 42.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a decline of 37.8%.
• Its expenses for the quarter were down by 31.1% QoQ and 57.1% YoY.
• The net profit decreased 272.5% QoQ and decreased 135.4% YoY.
• The earnings per share (EPS) of Pharmaids Pharmaceuticals Ltd stood at 0.63 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Pharmaids Pharmaceuticals Ltd is a company operating in the pharmaceutical industry. The company is involved in the development, manufacturing, and marketing of pharmaceutical products. While the specific products or services offered by Pharmaids Pharmaceuticals Ltd are not detailed in the provided data, it is crucial to note that companies in this industry typically engage in the production and distribution of drugs and related health products. Any recent major developments about the company are not available in the provided dataset, so we are not in a position to discuss recent strategic shifts or new product launches that might have impacted its performance.

Revenue

In the first quarter of fiscal year 2027 (Q1FY27), Pharmaids Pharmaceuticals Ltd reported a total income of ₹4.17 crores. This represents a significant decrease of 42.7% quarter-over-quarter (QoQ) from ₹7.28 crores in the fourth quarter of fiscal year 2026 (Q4FY26), and a 37.8% decline year-over-year (YoY) from ₹6.70 crores in the first quarter of fiscal year 2026 (Q1FY26). These changes in revenue highlight a notable reduction in the company's income over both periods, indicating fluctuations in its sales or revenue-generating activities.

Profitability

The profitability of Pharmaids Pharmaceuticals Ltd showed a marked improvement in Q1FY27. The company recorded a profit before tax (PBT) of ₹2.41 crores, in stark contrast to a loss of ₹1.46 crores in Q4FY26 and a loss of ₹7.17 crores in Q1FY26. This translates to a QoQ improvement of 265.1% and a YoY improvement of 133.6%. The company's profit after tax (PAT) also improved to ₹1.88 crores from a loss of ₹1.09 crores in Q4FY26 and a loss of ₹5.31 crores in Q1FY26, reflecting a QoQ increase of 272.5% and a YoY increase of 135.4%. These figures indicate a turnaround in profitability, despite the decline in total income. The earnings per share (EPS) rose to ₹0.63 in Q1FY27 from a negative ₹0.51 in Q4FY26 and a negative ₹1.41 in Q1FY26, showcasing significant improvements in shareholder returns over these periods.

Operating Metrics

Operating metrics for Pharmaids Pharmaceuticals Ltd reveal a substantial decrease in total expenses, which amounted to ₹5.96 crores in Q1FY27. This represents a 31.1% reduction from ₹8.65 crores in Q4FY26 and a 57.1% decrease from ₹13.88 crores in Q1FY26. The reduction in expenses could be a factor contributing to the observed profitability improvements. The tax expense for Q1FY27 was ₹0.54 crores, compared to a negative tax of ₹0.37 crores in Q4FY26 and a negative tax of ₹1.86 crores in Q1FY26, indicating a reversal from previous quarters where tax credits were recorded. These operating metrics suggest significant shifts in cost management and tax liabilities, which have been pivotal in the company's financial performance for the quarter.